Key terms
About GKOS
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GKOS news
Apr 15
7:35am ET
Glaukos price target raised to $107 from $102 at BTIG
Apr 11
7:01am ET
Glaukos price target raised to $100 from $85 at Mizuho
Apr 03
8:25am ET
Glaukos (GKOS) Gets a Buy from Stifel Nicolaus
Apr 03
7:07am ET
Glaukos receives permanent J-code for iDose TR
Apr 03
5:40am ET
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Glaukos (GKOS) and Omnicell (OMCL)
Mar 26
6:20am ET
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)
Mar 25
6:00am ET
Glaukos price target raised to $120 from $107 at Citi
Mar 22
7:07am ET
Truist Financial Reaffirms Their Buy Rating on Glaukos (GKOS)
Feb 28
7:13am ET
Glaukos to Present Periodic Investor Updates Online
Feb 25
11:56pm ET
Glaukos Corporation: Hold Rating with Cautious Optimism Amidst iDose Launch and Reimbursement Uncertainties
Feb 22
8:34am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Exact Sciences (EXAS), Moderna (MRNA) and Glaukos (GKOS)
Feb 22
8:03am ET
Piper Sandler Sticks to Its Buy Rating for Glaukos (GKOS)
Feb 22
7:27am ET
Buy Rating for Glaukos: A Comprehensive Analysis of Growth Drivers and Financial Stability
Feb 22
7:17am ET
Glaukos price target raised to $102 from $90 at BTIG
Feb 22
6:49am ET
Glaukos price target raised to $103 from $83 at Wells Fargo
Feb 22
6:29am ET
Glaukos price target raised to $107 from $101 at Citi
Feb 22
5:30am ET
Analysts Offer Insights on Healthcare Companies: GeneDx Holdings (WGS) and Glaukos (GKOS)
Feb 21
4:25pm ET
Glaukos affirms FY24 revenue view of $350M-$360M, consensus $356.3M
Feb 21
4:25pm ET
Glaukos reports Q4 EPS (63c), consensus (55c)
Feb 21
4:24pm ET
Glaukos Quarterly Summary: Performance Insights and Disclosures
Feb 16
7:37am ET
Piper Sandler Gives a Buy Rating to Glaukos (GKOS)
Feb 16
5:29am ET
Analysts’ Top Healthcare Picks: Ionis Pharmaceuticals (IONS), Glaukos (GKOS)
Jan 30
9:30pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Stryker (SYK), BioMarin Pharmaceutical (BMRN) and Glaukos (GKOS)
No recent press releases are available for GKOS
GKOS Financials
Key terms
Ad Feedback
GKOS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GKOS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
